Get Our FREE Newsletter

Sign Up

How DermTech Could Change Skin Cancer Testing — Or Fizzle Out

Spread the love

DermTech (NASDAQ: DMTK) is trying to redefine the process for identifying skin cancer. The current approach involves a visual inspection and an invasive biopsy — a highly inaccurate method that most patients don’t like. DermTech’s products help consumer avoid worrying about accu

This post was originally published on this site